Prodeon Medical's Urocross Expander System Receives FDA Clearance for Non-Permanent BPH Treatment
核心洞察
The FDA has cleared Prodeon Medical (搜索)'s Urocross Expander System (搜索), a novel non-permanent implant for treating lower urinary tract symptoms (搜索) associated with benign prostatic hyperplasia (搜索).
Clinical trial data from 240 patients showed 48.1% mean improvement in symptom scores at 12 months, with 74.5% of patients achieving clinically meaningful symptom relief.
The retrievable nitinol (搜索)-based implant remodels prostatic tissue over six months before removal, preserving sexual function and future treatment options.
The US Food and Drug Administration (搜索) has cleared Prodeon Medical (搜索)'s Urocross Expander System (搜索), marking the introduction of a novel non-permanent implant technology for treating lower urinary tract symptoms (搜索) associated with benign prostatic hyperplasia (搜索) (BPH (搜索)). The California-based company's innovative approach offers an alternative to existing treatments that rely on permanent implants or irreversible tissue ablation.
Revolutionary Non-Permanent Implant Technology
The Urocross (搜索) system utilizes a nitinol (搜索)-based structure that initiates prostatic urethral reshaping through constant, gentle pressure applied to obstructive prostatic lobes (搜索). This process effectively opens the urethral lumen (搜索) while preserving surrounding tissue integrity. The implant is designed for retrieval within six months, leaving no permanent foreign material behind.
"Unlike existing minimally invasive therapies that rely on permanent implants or irreversible tissue ablation, Prodeon Medical (搜索) introduces a new category of non-permanent, retrievable intervention for BPH (搜索)," said Thomas Palermo, President of Prodeon Medical.
Robust Clinical Evidence Supports FDA Clearance
The FDA clearance was supported by comprehensive data from Prodeon's Expander-2 pivotal trial, a large-scale multi-center randomized controlled trial involving 240 patients across 23 sites in the US and Canada. The study demonstrated significant clinical benefits with a favorable safety profile.
Key clinical outcomes included a mean improvement in International Prostate Symptom Score (IPSS) of 48.1% at 12 months post-implantation (six months post-retrieval). The system achieved a procedural responder rate of 74.5%, defined by the FDA as the percentage of patients with IPSS improvement above 30% at 12 months.
Notably, the trial reported no device or procedural-related serious adverse events in the Urocross (搜索) treatment arm, with preservation of sexual function and no patients reporting de novo sustained erectile or ejaculatory dysfunction (搜索).
Addressing Sexual Function Preservation
Analysis of 132 sexually active men in the Urocross (搜索) treatment arm revealed preservation and even improvement in sexual function. Erectile function scores improved from 16.0 at baseline to 17.7 at one year (p=0.006), while ejaculatory function scores increased from 8.2 to 10.1 (p<0.0001).
"The Urocross (搜索) Expander provides significant symptom relief with no negative impact on erectile and ejaculatory function. It's a compelling option for men seeking early intervention to treat BPH (搜索) without the sexual side effects common to certain medications or surgeries," said Dr. Kevin T. McVary, Professor of Urology at Loyola University Medical Center and Co-Principal Investigator of the Expander-2 Trial.
Simplified Retrieval Process
The intentional retrieval design represents a significant advancement over traditional prostatic implants. Analysis of 229 completed retrievals showed that 97% were successfully accomplished using flexible cystoscopy with the Urocross (搜索) Retrieval Sheath, with no retrievals requiring tissue resection prior to implant removal.
Post-operative pain scores were minimal, with 2.3/10 for implantation and 1.7/10 for retrieval at discharge, comparable to standard flexible cystoscopy procedures.
Market Impact and Clinical Paradigm Shift
The technology addresses a substantial unmet medical need, with approximately 40 million men in the US affected by BPH (搜索), according to the source materials. The condition's prevalence increases significantly with age, contributing to growing demand for minimally invasive treatments.
"BPH (搜索) management is not a singular intervention; it is a journey with longitudinal commitment to the patient's evolving quality of life," said Dr. Daniel B. Rukstalis, Chair of Urology at St. Catherine Hospital (搜索) and Co-Principal Investigator of the Expander-2 Trial. "Technologies like Urocross (搜索) that avoid permanent implants preserving future treatment options are becoming increasingly relevant in clinical decision-making."
The concept of First-Line Interventional Therapy (FIT) represents a paradigm-changing bridge between medical management and minimally invasive surgical treatment for BPH (搜索). Dr. Ricardo R. Gonzalez, Professor of Clinical Urology at Houston Methodist Hospital (搜索), noted that the non-permanent, retrievable design supports the system's candidacy as a FIT option.
Commercial Launch Plans
Prodeon Medical (搜索) plans to initiate a controlled US commercial release of the Urocross (搜索) system later this year. The company's approach reflects growing recognition among urologists of the importance of earlier intervention in BPH (搜索) to preserve bladder (搜索) function and mitigate disease progression.
The FDA clearance positions the Urocross Expander System (搜索) as a potentially transformative technology in BPH (搜索) management, offering clinicians and patients a treatment option that balances clinical efficacy with preservation of future therapeutic possibilities.